[{"arm_notes": "", "treatment_id": null, "treatment_name": "Experimental Drug;No Intervention No treatment;Inhaled budesonide group;Control group;Subjects with mild to moderate COVID-19 pneumonia will be treated with inhaled budesonide 800 microgram (200 microgram two puffs twice per day) plus standard usual care (SUC). The subjects will be prescribed with inhaled budesonide 800 microgram (200 microgram two puffs twice per day) with in 24 hour of admission. The inhaled budesonide 800 microgram per day will be stopped at the day of discharge or the subjects turn to severe pneumonia. Subject will be treated with antiviral drug. In case of severe pneumonia; we will stop the budesonide and the intravenous steroid and high flow oxygen therapy will be provided.;Subjects with mild to moderate COVID-19 pneumonia treated with standard usual care (SUC). The treatment will be provided to subjects according to theirs symptom. The oxygen supplement will be provided in case of SpO2 lower than 94 at room air. Subject will be treated with antiviral drug. In case of severe pneumonia; the intravenous steroid and high flow oxygen therapy will be provided.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 242, "treatment_name": "Budesonide", "treatment_type": "Corticosteroids", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]